GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
At the 2016 Annual Meeting of Stockholders held on December15,
2016, the stockholders of Galectin Therapeutics Inc. (Galectin or
the Company) re-elected each of the Companys directors that had
been nominated to serve until the next annual meeting or until
their successors are elected and have been qualified. The
stockholders also voted on a non-binding advisory resolution to
approve the compensation paid to the Companys named executive
officers and ratified the selection of Cherry Bekaert LLP as the
independent registered public accounting firm for the Company for
the year ending December31, 2016.
The final results of the voting on each matter of business at the
2016 Annual Meeting are as follows:
Election of Directors
|
Name |
VotesFor |
VotesWithheld |
BrokerNon-Votes |
|||||||||
|
Gilbert F. Amelio, Ph.D. |
10,677,510 | 573,344 | 14,976,838 | |||||||||
|
Kevin D. Freeman |
11,003,268 | 247,586 | 14,976,838 | |||||||||
|
Arthur R. Greenberg |
10,826,611 | 424,243 | 14,976,838 | |||||||||
|
John Mauldin |
10,692,692 | 558,162 | 14,976,838 | |||||||||
|
Gilbert S. Omenn, M.D., Ph.D. |
10,869,940 | 380,914 | 14,976,838 | |||||||||
|
Steven Prelack |
10,878,337 | 372,517 | 14,976,838 | |||||||||
|
Marc Rubin, M.D. |
10,870,558 | 380,296 | 14,976,838 | |||||||||
|
Peter G. Traber, M.D. |
10,844,660 | 406,194 | 14,976,838 |
Non-binding advisory resolution to approve the compensation
paid to the Companys named executive officers
|
Votes For |
Votes Against |
Votes Abstain |
Broker Non-Votes |
|||
|
10,263,034 |
844,997 | 142,823 | 14,976,838 |
Ratification of the selection of Cherry Bekaert LLP as the
independent registered public accounting firm for the Company for
the year ending December31, 2016
|
Votes For |
Votes Against |
Votes Abstain |
||
|
25,457,842 |
533,163 | 236,687 |
Additionally, the holder of the Companys Series B Convertible
Preferred Stock voted as a separate class to nominate and elect
two directors (the Series B Directors). Mr.James Czirr was
re-elected as a Series B Director and Dr.Theodore Zucconi was
elected as a new Series B Director, each to serve until the next
annual meeting or until their successors are elected and have
been qualified. The results of the voting for the Series B
Directors are as follows:
|
Name |
Votes For |
Votes Withheld |
Broker Non-Votes |
|||
|
James C. Czirr |
6,356,932 | n/a | ||||
|
Theodore Zucconi |
6,356,932 | n/a |
About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies. GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Recent Trading Information
GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) closed its last trading session down -0.023 at 0.880 with 99,266 shares trading hands.
